

Calquence® (acalabrutinib) - New indication

- On November 21, 2019, the <u>FDA announced</u> the approval of <u>AstraZeneca's Calquence (acalabrutinib)</u>, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Calquence is also approved for the treatment of adult patients with mantle cell lymphoma (MCL) who
 have received at least one prior therapy.
- CLL and SLL are cancers of lymphocytes, but they occur in different areas of the body. CLL occurs
 mainly in the blood and bone marrow, while SLL occurs mainly in the lymph nodes. Symptoms of CLL
 or SLL include low red blood cell counts, low platelet counts, fatigue, enlarged lymph nodes, and a
 higher risk of infection.
- The efficacy of Calquence for the treatment of CLL was demonstrated in two randomized, open-label, controlled studies. The indication for Calquence includes patients with SLL because it is the same disease. The first study, ELEVATE-TN, was conducted in 535 patients with previously untreated CLL. Patients received Calquence in combination with Gazyva (obinutuzumab), Calquence monotherapy, or Gazyva in combination with chlorambucil. Efficacy was based on progression-free survival (PFS).
 - In the Calquence combination arm, risk of disease progression or death was reduced by 90% (hazard ratio [HR] 0.10; 95% CI: 0.06, 0.17; p < 0.0001) vs. Gazyva in combination with chlorambucil and in the Calquence monotherapy arm it was reduced by 80% (HR 0.20; 95% CI: 0.13, 0.30; p < 0.0001).</p>
 - The median time to disease progression for patients treated with Calquence in combination with Gazyva or as a monotherapy has not yet been reached vs. 22.6 months (95% CI: 20, 28) for Gazyva in combination with chlorambucil.
- The second study, ASCEND, was conducted in 310 patients with relapsed or refractory CLL. Patients
 received Calquence monotherapy or an investigators choice of <u>Zydelig[®] (idelalisib)</u> plus a rituximab
 product or bendamustine plus a rituximab product.
 - In the Calquence arm, risk of disease progression or death was reduced by 69% (HR 0.31; 95% CI: 0.20, 0.49; p < 0.0001) vs. the investigator's choice comparator arm.
 - The median time to disease progression for patients treated with Calquence has not yet been reached vs. 16.5 months (95% CI: 14.0, 17.1) for the investigator's choice comparator arm.
- The recommended dose of Calquence for the treatment of CLL or SLL is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
 - Refer to the Calquence drug label for complete dosing recommendations for CLL, SLL, and MCL.
 - Refer to the Gazyva drug label for dosing recommendations when used in combination with Calquence.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.